Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

2016108 citationsJournal Article

Authors

Benoît Trottier

Jordan E. Lake · University of California, Los Angeles

Ken Logue

Cynthia Brinson

Lizette Santiago · Clinical Research Puerto Rico

Clare Brennan · Triangle

Justin Koteff · Triangle

Brian Wynne

Judy Hopking ·

Abstract

Data demonstrating non-inferiority of switching to ABC/DTG/3TC versus continuing current ART support ABC/DTG/3TC as an option when considering switch regimens in HIV-1-infected adults with stable viral suppression.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Antiviral Therapy

Volume 22, Issue 4, pp. 295-305

DOI: 10.3851/imp3166

Field-Weighted Citation Impact: 9.81